SCHEMBL7945567

SCHEMBL7945567

COc1ccc(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)cc1

nearest known ligand 0.75

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.75
SLC5A1 P13866 1/20 0.67
SLC5A2 P31639 1/20 0.67
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
IL2 P60568 1/20 0.60
POLB P06746 1/20 0.59
ACHE P22303 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187277 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL4187272 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL15533442 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL7744552 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL18022555 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL8388035 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL16689576 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL17623940 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL15589634 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A
SCHEMBL16785939 1.00 TYR (0.75) TYRSLC5A1SLC5A2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118649173-A Application of glycoside compound 深圳大学 2024-09-17 CN disclosed
CN-107428665-B Method for producing (meth) acrylic ester 东亚合成株式会社 2021-10-15 CN disclosed
CN-107406363-B Method for producing (meth) acrylic ester 东亚合成株式会社 2021-10-08 CN disclosed
CN-105683389-B Method for specifically labeling live bacteria comprising use of modified monosaccharide compounds 国家科学研究中心 2021-09-28 CN disclosed
CN-107709377-B Curable composition 东亚合成株式会社 2021-04-20 CN disclosed
EP-3063288-B1 A METHOD FOR LABELING SPECIFICALLY LIVING BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS CENTRE NAT RECH SCIENT (FR) 2020-12-02 EP disclosed
CN-107709376-B Curable composition 东亚合成株式会社 2020-10-30 CN disclosed
CN-107922555-B Curable composition 东亚合成株式会社 2020-08-28 CN disclosed
EP-3281933-B1 (METH)ACRYLATE MANUFACTURING METHOD TOAGOSEI CO LTD (JP) 2020-08-19 EP disclosed
US-10619058-B2 Curable composition TOAGOSEI CO., LTD. (JP) 2020-04-14 US disclosed
US-20170204044-A1 MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD TOAGOSEI CO., LTD. (JP) 2017-07-20 US disclosed
WO-2017079456-A1 SYNTHETIC ANTIGEN CONSTRUCTS AGAINST CAMPYLOBACTER JEJUNI THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2017-05-11 WO disclosed
EP-3133058-A1 MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD Toagosei Co., Ltd. (JP) 2017-02-22 EP disclosed
CN-106029628-A Multifunctional (meth)acrylate manufacturing method 东亚合成株式会社 2016-10-12 CN disclosed
EP-3063288-A1 A METHOD FOR LABELING SPECIFICALLY LIVING BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2016-09-07 EP disclosed
US-20160238609-A1 A METHOD FOR LABELING SPECIFICALLY LIVING AND BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2016-08-18 US disclosed
CN-105683389-A Method for specifically labeling live bacteria comprising use of modified monosaccharide compounds 国家科学研究中心 2016-06-15 CN disclosed
WO-2015063173-A1 A METHOD FOR LABELING SPECIFICALLY LIVING BACTERIA COMPRISING THE USE OF MODIFIED MONOSACCHARIDE COMPOUNDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-05-07 WO disclosed
EP-2868750-A1 A method for labeling specifically living bacteria comprising the use of modified monosaccharide compounds Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2015-05-06 EP disclosed
US-6245902-B1 USEFUL FOR PREPARING C-GLYCOSIDE ANALOGS OF GANGLIOSIDES, PEPTIDES, AND PROTEINS, AS WELL AS SYNTHETIC INTERMEDIATES USEFUL FOR THE PREPARATION OF THE PRECURSORS UNIVERSITY OF IOWA RESEARCH FOUNDATION 2001-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204044-A1 MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD MMAB, AMD1, ADH5 TYR 1394/4885SLC5A1 4540/4885SLC5A2 4670/4885
US-10619058-B2 Curable composition ZMYND8, AZI2, KAT2A TYR 1051/4885SLC5A1 4736/4885SLC5A2 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.